These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9805022)

  • 1. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.
    King SM; Watson H; Heurter H; Ricketts M; Elsaadany S
    CMAJ; 1998 Oct; 159(7):771-4. PubMed ID: 9805022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: integrating science, legal duties and ethical mandates.
    Caulfield T; Dossetor J; Boshkov L; Hannon J; Sawyer D; Robertson G
    CMAJ; 1997 Nov; 157(10):1389-92. PubMed ID: 9371070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood recipients and CJD: to notify or not to notify, that is the question.
    Sibbald B
    CMAJ; 1998 Oct; 159(7):829-31. PubMed ID: 9805032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of being placed at risk of Creutzfeldt-Jakob disease: a qualitative study of blood donors to variant CJD cases and patients potentially surgically exposed to CJD.
    Elam G; Oakley K; Connor N; Hewitt P; Ward HJ; Zaman SM; Chow Y; Marteau TM
    Neuroepidemiology; 2011; 36(4):274-81. PubMed ID: 21757956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.
    Menache D; O'Malley JP
    Biologicals; 1996 Sep; 24(3):277-83. PubMed ID: 8978926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian hospital-based HIV/hepatitis C look-back notification program.
    Heddle N; Kelton JG; Smaill F; Foss K; Everson J; Janzen C; Walker C; Jones M; Hammons D
    CMAJ; 1997 Jul; 157(2):149-54. PubMed ID: 9238143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disclosure of medical error to parents and paediatric patients: assessment of parents' attitudes and influencing factors.
    Matlow AG; Moody L; Laxer R; Stevens P; Goia C; Friedman JN
    Arch Dis Child; 2010 Apr; 95(4):286-90. PubMed ID: 19948514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creutzfeldt-Jakob disease and blood transfusion.
    Fernandez Lopez MJ; Van Everbroeck B; Pals P; Martin JJ; Cras P
    Acta Neurol Belg; 1998 Sep; 98(3):247-51. PubMed ID: 9801705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood recipient notification for hepatitis C in Prince Edward Island.
    Van Til LD; Sweet LE
    CMAJ; 2000 Jan; 162(2):199-202. PubMed ID: 10674052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study.
    Dorsey K; Zou S; Schonberger LB; Sullivan M; Kessler D; Notari E; Fang CT; Dodd RY
    Transfusion; 2009 May; 49(5):977-84. PubMed ID: 19170987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creutzfeld-Jakob disease: the Grace General Hospital experience.
    Pauls F; Hayes J; Read J
    Leadersh Health Serv; 1996; 5(6):42-3. PubMed ID: 10163983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
    Ironside JW; Head MW
    Haemophilia; 2004 Oct; 10 Suppl 4():64-9. PubMed ID: 15479374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disclosure of severe development disability: a survey of parents' experiences and preferences at an Israeli child development center].
    Lavi E; Rosenberg J
    Harefuah; 2005 May; 144(5):322-6, 383. PubMed ID: 15931894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informing a recipient of blood from a donor who developed Creutzfeldt-Jakob disease: the characteristics of information that warrant its disclosure.
    Steinberg D
    J Clin Ethics; 2001; 12(2):134-40. PubMed ID: 11642064
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors associated with disclosure of diagnosis to children with HIV/AIDS.
    Wiener LS; Battles HB; Heilman N; Sigelman CK; Pizzo PA
    Pediatr AIDS HIV Infect; 1996 Oct; 7(5):310-24. PubMed ID: 11361489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives.
    Vamvakas EC
    J Clin Apher; 1999; 14(3):135-43. PubMed ID: 10540369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA; Turner ML
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.